Immunocore
Highly Engaged Employees
Highly Engaged EmployeesChemicals & Related Products · United Kingdom · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
92 Park Drive, Abingdon, Oxfordshire, OX...Phone Number
+441235438600Website
www.immunocore.comRevenue
$430.8 MillionStock Symbol
IMCRIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Immunocore
Founded in 2008, Immunocore Limited is a privately owned British clinical-stage biotechnology company. It develops biological drugs to treat cancer, infectious diseases, and autoimmune diseases using soluble T-cell receptor technology. They are headquartered in Milton, United Kingdom.Explore more
Immunocore Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunocore your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Immunocore has new funding data
Check out if Immunocore is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Immunocore recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Immunocore
Immunocore, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Immunocore had a recent Job posting/layoffs
Product Launch: Get notified when Immunocore launches new products
Check if Immunocore has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Immunocore
Compare insights from companies similar to Immunocore, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immunocore is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Immunocore is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Immunocore.
Immunocore financials insights
Gather financial insights about Immunocore, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$320M
2020
Series B
$130M
2021
Series C
$75M
Stock Offering
$297.1M
Immunocore Tech Stack
A closer look at the technologies used by Immunocore
See more technologies
Most Recent Scoops
Project
Immunocore has opened its Phase I trial for IMC-S118AI, a type 1 diabetes candidate designed to bind to preproinsulin expressed exclusively on beta cells of the pancreas, with the first patient dosing expected in the coming weeks. The study is designed to provide early evidence of target engagement and immune modulation, using C-peptide levels as a clinically validated endpoint.
Medical Research, Clinical Operations
Project
Immunocore is advancing ATOM, the only uveal melanoma registrational trial actively enrolling in the adjuvant setting, in which high-risk patients are randomized to KIMMTRAK or observation with relapse-free survival as the primary endpoint. The study, sponsored by EORTC, is enrolling across multiple European countries and has recently expanded enrollment to the US.
Clinical Operations
Project
Immunocore is advancing TEBE-AM, a randomized Phase III trial evaluating KIMMTRAK monotherapy, KIMMTRAK plus pembrolizumab, or a control arm in melanoma patients who have progressed on checkpoint inhibitors and, if applicable, targeted therapy, with overall survival as the primary endpoint. Enrollment is nearing the target of 540 patients, with top-line data expected as early as the end of 2026.
Medical Research, Clinical Operations
Project
Immunocore is expanding its PRAME franchise (brenetafusp) into ovarian cancer and non-small cell lung cancer, evaluating the therapy in combination with chemotherapy in platinum-resistant ovarian cancer, in combination with bevacizumab in platinum-sensitive maintenance settings, and as monotherapy across molecular subsets in lung cancer. Data from these ovarian and lung cohorts are expected to be presented later in 2026.
Medical Research, Clinical Operations
Open Position
Immunocore News & Media
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferencesImmunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript
Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsRyan BakerBahija Jallal - CEO & Executive...Immunocore Q2 Earnings Call Highlights
Immunocore (NASDAQ:IMCR) reported continued growth for KIMMTRAK in the second quarter and first half of 2026, while advancing three late-stage melanoma trials and early-stage programs in oncology, HIV and Type 1 diabetes. The company recorded $223 million in KIMMTRAK net sales during the first halfImmunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Strong Kimtrak Growth and ...
Immunocore reports robust first-half revenue, advances multiple Phase 3 trials, and maintains a strong cash position despite expected headwinds.
Read more news
Top Chemicals & Related Products Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunocore
Sign Up For FreeTo access detailed company insights
Founded in 2008, Immunocore Limited is a privately owned British clinical-stage biotechnology company. It develops biological drugs to treat cancer, infectious diseases, and autoimmune diseases using soluble T-cell receptor technology. They are headquartered in Milton, United Kingdom.... Read More
